TRVI stock icon

Trevi Therapeutics
TRVI

$2.84
2.07%

Market Cap: 200M

 

About: Trevi Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of the investigational therapy Haduvio (oral nalbuphine ER) for the treatment of chronic cough in adults with idiopathic pulmonary fibrosis, or IPF, and other chronic cough indications, and for the treatment of prurigo nodularis. Haduvio is an oral extended-release formulation of nalbuphine.

Employees: 25

0
Funds holding %
of 6,702 funds
0
Analysts bullish %
of 5 analysts
News positive %

Fund manager confidence

Based on 2024 Q1 SEC filings by fund managers ($100M+ AUM)

340% more first-time investments, than exits

New positions opened: 22 | Existing positions closed: 5

300% more call options, than puts

Call options by funds: $8K | Put options by funds: $2K

154% more capital invested

Capital invested by funds: $70M [Q4 2023] → $178M (+$108M) [Q1 2024]

27% more funds holding

Funds holding: 63 [Q4 2023] → 80 (+17) [Q1 2024]

7.03% less ownership

Funds ownership: 81.8% [Q4 2023] → 74.77% (-7.03%) [Q1 2024]

41% less repeat investments, than reductions

Existing positions increased: 16 | Existing positions reduced: 27

Research analyst outlook

5 Wall Street Analysts provided 1 year price forecasts over the past 6 months

Low target
$7
146%
upside
Avg. target
$8
182%
upside
High target
$9
217%
upside

5 analyst ratings

positive
100%
neutral
0%
negative
0%
Rodman & Renshaw
Brandon Folkes
146%upside
$7
Buy
Initiated
13 Jun 2024
Needham
Serge Belanger
182%upside
$8
Buy
Reiterated
8 May 2024
Needham
Serge Belanger
182%upside
$8
Buy
Reiterated
9 Apr 2024
Oppenheimer
Leland Gershell
217%upside
$9
Outperform
Maintained
21 Mar 2024
Needham
Serge Belanger
182%upside
$8
Buy
Reiterated
21 Mar 2024

Financial journalist opinion